TY - JOUR T1 - Sofosbuvir with ribavirin is safe and effective in hepatitis C genotype 1 with unfavourable pretreatment characteristics JF - Evidence Based Medicine JO - Evid Based Med SP - 90 LP - 90 DO - 10.1136/eb-2013-101592 VL - 19 IS - 3 AU - McKenzie C Ferguson Y1 - 2014/06/01 UR - http://ebm.bmj.com/content/19/3/90.abstract N2 - Commentary on: Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavourable treatment characteristics: a randomised clinical trial. JAMA 2013;310:804–11.OpenUrlCrossRefPubMedWeb of Science Treatment of hepatitis C virus (HCV) has improved with new direct-acting antiviral therapies, resulting in improved sustained virological response (SVR) rates, as compared with the treatment with pegylated interferon and ribavirin (RBV).1 ,2 Despite these improvements, direct-acting agents have been linked to resistance when used without interferon therapy. The guidelines recommend their use in combination with peginterferon α and RBV as optimal therapy in HCV genotype 1.1 ,2 However, this addition adds complexity to the medication regimen, potentially causing adverse effects and potential for drug interactions.2 The aim of this phase 2 study … ER -